Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| IMMUNOVANT | 13 | 1 | 0,00 % | ||
| ULTRAGENYX | 8 | - | -3,08 % | ||
| BIONTECH | 7 | 13 | +0,13 % | ||
| REGENERON PHARMACEUTICALS | 6 | 22 | -1,15 % | ||
| APELLIS PHARMACEUTICALS | 6 | 4 | -0,19 % | ||
| BIOGEN | 5 | 54 | -0,20 % | ||
| PHARVARIS | 5 | - | -0,81 % | ||
| AMGEN | 3 | 27 | -0,07 % | ||
| INCYTE | 3 | 25 | -2,28 % | ||
| HARMONY BIOSCIENCES | 3 | 17 | 0,00 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:26 | Grifols' Canadian licence restricted after plasma donor deaths | 1 | Financial Post | ||
| Do | NewAmsterdam Pharma Company N.V.: NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| Do | Oppenheimer reiterates Pharvaris stock rating on trial timeline | 1 | Investing.com | ||
| Do | Truist senkt Kursziel für Upstream Bio wegen verzögertem Studienzeitplan | 4 | Investing.com Deutsch | ||
| Do | Vanda Pharmaceuticals: Chefjurist Timothy Williams kündigt Rücktritt an | 3 | Investing.com Deutsch | ||
| Do | Truist cuts Upstream Bio stock price target on trial timeline | 2 | Investing.com | ||
| Do | Regeneron partners with TriNetX for health data access | 5 | Investing.com | ||
| Do | TriNetX, LLC.: TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions | 278 | PR Newswire | Under the collaboration, TriNetX will provide Regeneron with secure, licensed access to TriNetX's current and future de-identified health data from approximately 300 million individuals (170 million... ► Artikel lesen | |
| Do | Regeneron Pharmaceuticals, Inc.: Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions | 3 | GlobeNewswire (USA) | ||
| Do | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| Do | Esperion sells Japan royalty rights for $50 million to Athyrium | 2 | Investing.com | ||
| Do | Relay Therapeutics, Inc.: Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026 | 4 | GlobeNewswire (USA) | ||
| Do | Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) | 4 | GlobeNewswire (USA) | ||
| Do | Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| Do | Esperion Therapeutics, Inc.: Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst (bumetanide nasal spray) | 1 | GlobeNewswire (USA) | ||
| Do | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 216 | Business Wire | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted five newly-hired employees inducement options to purchase an... ► Artikel lesen | |
| Do | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Do | Vericel secures $197M BARDA deal, boosting NexoBrid supply plans | 1 | Seeking Alpha | ||
| Do | Vanda Pharmaceuticals Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Do | MediWound Ltd.: MediWound Reports BARDA Contract Award to Vericel for NexoBrid Valued at up to $197 Million | 1 | GlobeNewswire (USA) |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.